Enjoy complimentary customisation on priority with our Enterprise License!
The biodefense market size is forecast to decrease by USD 7.16 billion at a CAGR of 4.96% between 2023 and 2028. The market is experiencing significant growth due to the increasing threat posed by hazardous biological agents and the need for preventative steps in industrialized nations. The market is witnessing a rise in product launches and strategic alliances among key players, with a focus on developing advanced bio-threat-detecting tools, nanotechnology, gene chips, and plasmid DNA constructions for the detection of infections and drug development. The lack of information about bioengineered organisms attacks presents a challenge, necessitating the development of sophisticated biodefense systems. The healthcare infrastructure in various countries is undergoing transformation to accommodate the demands of biomedical innovation and the production of stocks of vaccines and treatments. The market's future growth is expected to be driven by the continued efforts to enhance human health and safeguard against biothreats.
The market encompasses the production and distribution of medical measures and military measures to counteract biological threats. These threats include anthrax spores, botulism, and various infectious agents such as bacteria and viruses, as well as biological toxins, chemical agents, and radioactive agents. Biodefense is crucial in preventing the use of biological weapons, which can be engineered through genetic engineering and biotechnology to create new and deadly organisms. Anthrax, for instance, is a significant concern due to its potential use as a weapon, and medical countermeasures are essential to mitigate its effects. Biosecurity measures are also vital in safeguarding against biological threats, whether they originate from natural sources or intentional releases. The market for biodefense continues to grow as the threat landscape evolves and new technologies emerge to address these challenges.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The vaccines segment is estimated to witness significant growth during the forecast period. Biodefense vaccines play a crucial role in safeguarding populations against intentional biological attacks, emerging infectious diseases, and bioterrorism incidents. These vaccines are engineered to prevent the dissemination of pathogens that could be employed in deliberate attacks or emerge naturally. Several biodefense vaccines have been engineered and authorized for use in various nations, serving as indispensable resources in national preparedness and response strategies. For instance, Emergent BioSolutions' anthrax vaccine adsorbed (AVA) is one of the primary vaccines utilized to shield against anthrax, a bacterial agent that can be weaponized for bioterrorism. AVA has been granted approval by regulatory authorities in the United States and other countries and is maintained in stockpiles for use during anthrax attacks.
Furthermore, biodefense vaccines are also essential in mitigating economic losses caused by fatal viruses such as Zika, Flu, Ebola, and other diseases. Furthermore, biodefense vaccines are instrumental in protecting against chemical and nuclear agents, as well as biological threats from smallpox, botulism, and other hazardous organisms. In the face of increasing biological, chemical, radiological, and nuclear threats, utilizing medical countermeasures, including vaccines, is essential for effective response and prevention strategies.
Get a glance at the market share of various segments Request Free Sample
The vaccines segment was valued at USD 8.21 billion in 2018 and showed a gradual increase during the forecast period.
Rest of World (ROW) is estimated to contribute 11% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The region is projected to witness the fastest growth in the market due to the rising threat of bioterrorism. Biological threats, including fatal viruses such as Zika, Flu, and Ebola, pose significant risks, particularly in regions with low research capabilities. Additionally, the possibility of chemical, nuclear, and radiological agent attacks is a major concern. The devastating consequences of such incidents, both in terms of human lives and economic loss, necessitate the utilization of medical countermeasures. The potential for bioterrorism in a region that comprises over half of the world's population could have catastrophic effects. Notable examples include the Smallpox virus and Botulism toxin. In light of these concerns, governments and organizations are investing heavily in biodefense research and development to mitigate these threats.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Increasing threat posed by biological agents is the key driver of the market. The market has experienced significant growth due to the increasing threat of biological agents, including anthrax spores from Bacillus anthracis, as well as viruses, fungi, and toxins. Anthrax vaccines from companies like Emergent Bioscience play a crucial role in medical and military measures against this bacterial disease. The need for biodefense measures has been underscored by recent events such as the Ebola virus outbreak, the Zika virus epidemic, and the ongoing COVID-19 pandemic.
Furthermore, these incidents have highlighted the devastating impact of infectious diseases and the importance of strengthening preparedness and response capabilities. The threat landscape continues to evolve, with emerging infectious agents, drug-resistant pathogens, and the potential for engineered bioweapons posing new challenges to biosecurity. Biological toxins and infectious agents, whether naturally occurring or engineered, can cause significant harm and require effective countermeasures. Biological warfare, whether intentional or accidental, can have catastrophic consequences, making strong biodefense measures essential for protecting populations and critical infrastructure.
Rising product launches and strategic alliances among market participants is the upcoming trend in the market. The market is witnessing significant growth due to the increasing threats from anthrax spores and other infectious agents, including bacteria, viruses, fungi, and toxins.
Furthermore, biological warfare and biosecurity concerns have heightened the demand for medical measures and military measures to combat these threats. companies in the market are responding with strategic alliances, such as partnerships, mergers and acquisitions (M&A), and new product launches. These strategic moves will help companies expand their product offerings and strengthen their market position.
Lack of information about bioengineered organism attacks is a key challenge affecting market growth. The market encompasses various medical and military measures aimed at preventing, detecting, and responding to threats posed by infectious agents, biological toxins, and genetically altered organisms. These threats can include naturally occurring diseases such as Anthrax caused by Bacillus anthracis spores, as well as potential biological warfare agents and other companies have developed Anthrax vaccines to mitigate the risks associated with this bacterium.
However, the use of genetically modified organisms in scientific research and potential malicious applications poses significant challenges to the market. The unique properties of these organisms and the clinical symptoms displayed by infected individuals may surpass conventional diagnostic and preventive measures. The potential for creating new pathogens or biological threat agents with exclusive properties is a major concern for biosecurity and public health. The market is, therefore, essential in addressing these challenges and ensuring the development of effective countermeasures against a wide range of biological threats.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Alnylam Pharmaceuticals Inc. -The company offers biodefense solution such as RNAi therapeutics for the treatment of amyloidosis, hyperoxaluria, and porphyria.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market encompasses medical measures and military strategies aimed at mitigating threats posed by infectious agents, biological toxins, bacteria, viruses, fungi, and chemical & nuclear agents. These threats include anthrax spores, anthrax (Bacillus anthracis), smallpox, botulism, radiological threats, and nuclear threats, among others. The market is driven by the need to develop vaccines and medical countermeasures against fatal viruses such as Ebola, Zika, flu, and viral hemorrhagic fever, as well as bacterial diseases like brucellosis, cholera, and plague. Biodefense initiatives also focus on the detection and prevention of biothreat agents, including food poisoning, tularemia, and ebola. Scientific advancements in biotechnology, genetic engineering, and nanotechnology play a crucial role in the development of sophisticated biodefense systems.
Furthermore, biodefense laws and support from governments, public health services, and industrialized nations have led to efforts in vaccine development, clinical trials, and the creation of stocks of vaccines and bio-threat-detecting tools. The market also includes the development of technologically sophisticated products, such as detectors/triggering devices, samplers, reagents, and identifiers, for the detection of infections and the production of vaccines using novel vaccination technologies like vector technology and oral doses. The immune response to bioterrorism agents and threats is a key focus of biodefense initiatives, with efforts to develop hyperimmune development programs, plasma-derived therapy, and preventative steps to minimize economic loss from bio-incidents.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
166 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Decelerate at a CAGR of 4.96% |
|
Market growth 2024-2028 |
USD -7.16 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
-13.22 |
|
Regional analysis |
Asia, North America, Europe, and Rest of World (ROW) |
|
Performing market contribution |
Rest of World (ROW) at 11% |
|
Key countries |
US, UK, Germany, China, and India |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Alnylam Pharmaceuticals Inc., Appili Therapeutics Inc., AstraZeneca PLC, Bavarian Nordic AS, Chimerix Inc., Dynavax Technologies Corp., Elusys Therapeutics Inc., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Merck and Co. Inc., Neogen Corp., Novavax Inc., Porton Biopharma Ltd., Sanofi SA, Serum Institute of India Pvt. Ltd., SIGA Technologies Inc., Soligenix Inc., Tonix Pharmaceuticals Holding Corp., Zoetis Inc., and Johnson and Johnson |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
